Moderna Inc

+17.05 (+6.43%)
5:02:58 PM EDT: $282.55 +0.17 (+0.06%)
Other Pre-Announcement

Rovi Says 2023 Long Term Guidance Expected To Be Achieved In 2021

Published: 11/16/2021 07:06 GMT
Moderna Inc (MRNA) - 2023 Long Term Guidance Expected to Be Achieved in 2021.
Expects the Cmo Business to Increase by Between 2 and 2.5 Times, Including Production of the Covid-19 Vaccine.
Aims to Become a Long-term Manufacturing Partner for Moderna.
Sees 2022 Operating Revenue Growth Rate at Mid-single-digit.
Is Increasing Remuneration to Shareholders Up to 125 Million Euros From November 3, for a Twelve-month Period.
Investment in 2 New Lines for Compounding, Filling, Automatic Visual Inspection and Labeling at Rovi’s San SebastiÁn De Los Reyes (madrid) Facility.
These Lines Will More Than Double the Number of Vials for Which There is Fill-finish Capacity at This Facility.
Dara 2 Expected to Come Into Operation in Q4 2021.
Dara 3 Expected to Come Into Operation Between Q2 and Q3 2022.